Paracetamol EQL Pharma approved

The drug Paracetamol EQL Pharma has now been approved for sale by the Swedish Medicines Agency.

Paracetamol EQL Pharma is used for aches and pains of different types (e.g., headache, toothache, menstrual pain, muscle and joint pain and rheumatic pain) and fever (e.g. during colds).

Paracetamol is a very common drug and sells in high volumes in all markets in Europe. EQL Pharma has found their niche by choosing strengths and packaging variants that are less exposed to competition but still have an interesting market size.
This niche market has a turnover of approximately SEK 20 million annually and is home to a few competitors, in line with the EQL Pharma's long-term strategy.

The product is expected to be launched in the second half of 2018.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

About EQL Pharma 

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets eight (8) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.